Trump signs order to hasten review of psychedelics

President Trump signed an order to expedite the review process for psychedelics, aiming to accelerate research into their potential medical applications. This action comes despite psychedelics like Ibogaine remaining in the federal government's most restrictive category for illegal, high-risk drugs. The Trump administration is seeking to ease current restrictions to spur studies on using these substances for conditions such as severe depression. This initiative could lead to significant changes in how psychedelics are researched and potentially utilized for therapeutic purposes in the United States.